SAN DIEGO, Oct. 19, 2017 -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share. The syndicate of investors in the private placement was comprised of new and existing investors, including Great Point Partners, LLC, BB Biotech AG, Prosight Capital, Broadfin Capital, LLC and certain other institutional investors. The gross…

Data Highlight Advantages of CD101 in Difficult-to-Treat Infections SAN DIEGO, Sept. 25, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its novel echinocandin antifungal CD101 will be presented at two upcoming infectious disease meetings. CD101 abstracts have been accepted for presentation at both IDWeek 2017 in San Diego from October 4-8 and at the 8th Trends in Medical Mycology (TIMM) meeting…

SAN DIEGO, Sept. 18, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at two upcoming investor conferences. Cantor Fitzgerald 2017 Global Healthcare Conference, New York, September 25, 2017 at 10:20 a.m. EDT (7:20 a.m. PDT)Ladenburg Thalmann 2017 Healthcare Conference, New York, September 26, 2017 at 8:30 a.m. EDT (5:30 a.m. PDT) A…

SAN DIEGO, Sept. 07, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., the company's president and chief executive officer, will participate in a keynote panel at the 2017 World Antimicrobial Resistance Congress being held September 14-15 in Washington, D.C. The interactive panel will focus on a discussion of key challenges for advancing antibiotic development and incentives that can help spur innovation in the…

SAN DIEGO, Aug. 09, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2017 and provided an update on its corporate activities and product pipeline. "We began the second quarter of 2017 by welcoming the financial community to our inaugural Investor Day, in New York, where we described plans for our CD101 and Cloudbreak™ programs and heard presentations from…

Data published in Antimicrobial Agents and Chemotherapy demonstrate CD101 has superior tissue and lesion penetration compared to the current standard of care SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including anti-infective immunotherapies, today announced publication of data from an in vivo study investigating the deep tissue distribution of CD101, Cidara's next-generation echinocandin agent, compared to the current first-line treatment, micafungin, in the setting of intra-abdominal candidiasis (IAC), one of…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will be participating in a panel discussion at the 2017 Infectious Diseases Summit being held July 13-14 in Baltimore, Maryland. The interactive panel will be part of the Summit's 14th Anti-Infectives Partnering & Deal-Making Conference that will focus on the types and availability of economic incentives to spur…

Panel Discussion Will Highlight Urgent Needs and Opportunities in Antifungal Development SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer, will participate in a panel discussion at the 2017 BIO International Convention being held June 19-22 in San Diego. The panel will focus on the increasing prevalence of fungal infections and antifungal resistance, and highlight the urgent…

Data Highlight Expanded Utility of CD101 for Potential Treatment and Prevention of Serious Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its novel echinocandin antifungal CD101 will be presented at two upcoming, major medical meetings. CD101 abstracts have been accepted for presentation at both ASM Microbe 2017 in New Orleans, Louisiana from June 1-5 and at the 22nd…

SAN DIEGO, May 10, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and product pipeline. "We are excited about the progress we are making on our CD101 IV and Cloudbreak™ programs, which we discussed at our recent investor day," said Jeffrey Stein, Ph.D., president and chief executive officer of…